Januvia
Indicated to manage blood glucose levels in adults and formulated to support glycaemic control in type 2 diabetes.
Strengths: 50 · 100mg
Where to Check Availability
Medicine details
- Conditions
- Alternative names
Xelevia
- Therapeutic class
Dipeptidyl Peptidase-4 (DPP-4) Inhibitor
- Pharmacological class
DPP-4 Inhibitor
- Contraindications
hypersensitivity to sitagliptin; history of pancreatitis
- Minor side effects
nausea; upper respiratory tract infection
- Moderate side effects
hypoglycaemia when combined with insulin or sulphonylureas; constipation
- Dosage forms
Film-coated tablet
- Administration route
Oral use
- Prescription status
POM
- Manufacturer
Merck Sharp & Dohme
- Onset Time
1–4 hours
- Duration
24 hours
- Storage instructions
Store below 30°C in the original container.
- Drug interactions
digoxin
- Age restrictions
Not indicated for patients under 18 years.
Precautions and warnings
monitor for signs of pancreatitis; use with caution in patients with renal impairment
Serious side effects
acute pancreatitis — requires immediate medical attention; bullous pemphigoid — requires immediate medical attention
Patient summary
Indicated to manage blood glucose levels in adults and formulated to support glycaemic control in type 2 diabetes.
Mechanism of action
Sitagliptin works by inhibiting the DPP-4 enzyme, which breaks down incretin hormones. By increasing the levels of these active hormones, it stimulates insulin release when blood sugar is high and lowers glucose production by the liver between meals.
Pregnancy and breastfeeding
Pregnancy: Not recommended. Breastfeeding: Not recommended as it is unknown if sitagliptin is excreted in human milk.
Januvia
Indicated to manage blood glucose levels in adults and formulated to support glycaemic control in type 2 diabetes.
Editorial Notes
- Active ingredient(s): Sitagliptin
- Listed indication(s): Type 2 Diabetes Mellitus
Usually available as
- 30 tablets - 50 mg961-50-mg-11481
- 30 tablets - 100 mg961-100-mg-11487